NCT06642363View on ClinicalTrials.gov

The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Polycystic Ovary Syndrome

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 22, 2024

Primary Completion Date

July 22, 2025

Study Completion Date

July 22, 2025

Conditions
PCO - Polycystic OvariesObesity and Obesity-related Medical Conditions
Interventions
DRUG

"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"

"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"

DRUG

Placebo

The placebo group will take one capsule containing corn starch in a wrapped and covered form and the appearance of ASX supplementation (blinding).

Trial Locations (1)

8174673461

RECRUITING

Isfahan university of medical sciences, Isfahan

All Listed Sponsors
lead

Isfahan University of Medical Sciences

OTHER